Loading
Rucaparib maintenance after platinum chemotherapy kept 60% of 42 patients progression-free at six months, with responses in germline BRCA2, germline PALB2 and somatic BRCA2 carriers, widening the group PARP inhibitors may help beyond POLO's germline BRCA rule.
Investigator-initiated single-arm phase 2: advanced pancreatic cancer with a germline or somatic pathogenic variant in BRCA1, BRCA2 or PALB2 after at least 16 weeks of platinum without resistance; chemotherapy stopped and rucaparib 600 mg twice daily given until progression. Of 46 enrolled, 42 were evaluable (27 gBRCA2, 7 gBRCA1, 6 gPALB2, 2 sBRCA2). Progression-free survival at 6 months was 59.5%, median 13.1 months; median overall survival 23.5 months; 12-month progression-free survival 54.8%. Response in 36 measurable patients was 41.7% (3 complete), disease control 66.7%, median duration 17.3 months; responses in gBRCA2 (11 of 27), gPALB2 (3 of 6) and sBRCA2 (1 of 2).
It is the evidence that PALB2 and somatic BRCA2 belong in the PARP inhibitor conversation even though the olaparib label stops at germline BRCA.
Shares Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations, PALB2, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline vs somatic mutations.
Shares PALB2, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline vs somatic mutations, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma.
Shares Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations, PALB2, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline vs somatic mutations.
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD), Journal of Clinical Oncology.
Shares PALB2, Germline BRCA1/2 pathogenic variant (gBRCAm), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD).
Shares PALB2, Germline BRCA1/2 pathogenic variant (gBRCAm), Germline vs somatic mutations, BRCA1 / BRCA2 (HRD).
Shares Robert H. Vonderheide, Abramson Cancer Center, University of Pennsylvania, Pancreatic ductal adenocarcinoma.
Shares Germline BRCA1/2 pathogenic variant (gBRCAm), BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, BRCA1 / BRCA2 (HRD), Metastatic pancreatic ductal adenocarcinoma.